Updated: 20/03/17 : 05:55:29Printable Version
ProTek Medical, a Molex company, today announced a restructuring of its operations in Sligo and informed employees that after incurring significant losses, it is introducing a cost reduction plan to better align its cost base with its current level of sales.
In a statement the company said, "Restoring the company to profitability to support future growth will involve a combination of proposed redundancies as well as efficiency improvements at all levels throughout the plant. It is expected that up to 25 roles will be impacted, subject to a 30-day consultation period with employee representatives.
"ProTek is focused on the future of its Sligo plant [Finisklin Business Park]
and it is committed to building capabilities that will prepare the company for profitable growth and innovative opportunities in areas such as connected health.
"The Company regrets the impact that this proposed decision will have on affected employees and it in no way reflects on the quality of their contribution to the business. The Company’s current level of sales and its financial position means it must consider these actions.
"ProTek is committed to providing employees who may be affected with resources and support to assist them in the transition.
This redundancy proposal may affect up to 25 employees at the ProTek Medical site, which currently has 166 employees.
Getting its cost structure in line with its revenue is necessary to make ProTek Medical more competitive and support its future growth.
ProTek Medical is a leading provider of Engineering, Cleanroom Injection moulding and manufacturing solutions for the global medical industry.
Molex acquired ProTek Medical in May 2015.
Molex sites in Letterkenny and Shannon are not affected.